Home » More Companies Quit Hepatitis C Drug Production
Health Metro News

More Companies Quit Hepatitis C Drug Production

U.S. drugmaker Merck & Co said on Friday it would discontinue developing an experimental drug combination for chronic hepatitis C, as competition rises and patient population shrinks.

The decision was made after reviewing mid-stage trial data of the treatments, said the company, which currently sells hepatitis C drug Zepatier.

Merck is the latest drugmaker to move away from the hepatitis C market.

READ ALSO:Nigerian Professor Invents HIV/AIDS Drug

Earlier this month, Janssen Sciences Ireland UC, a unit of Johnson & Johnson, said it would discontinue further development of its hepatitis C research.

Hepatitis C drugmakers have been struggling with slowing sales growth.

Market leader Gilead Sciences has seen total sales of its hepatitis C drugs – Sovaldi, Harvoni and Epclusa – sharply drop to $2.9 billion in the second quarter ended June 30 from $4 billion a year earlier.

Hepatitis C causes inflammation of the liver that can lead to diminished organ function or its failure.

An estimated 2.7 million to 3.9 million people in the United States have chronic hepatitis C infection, according to the Centers for Disease Control and Prevention.

About the author

TheHeat Nigeria

I am a family man with a golden heart for children. I am smart and creative.

Add Comment

Click here to post a comment

Leave a Reply


  • banner125x125_02.jpg


Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 338 other subscribers